Dear all, We are writing to update you on the progress of the PACT21-CASSANDRA study: A randomized phase II study comparing short- or long-term preoperative chemotherapy with the mFOLFIRINOX regimen (fluorouracil, levoleucovorin calcium, irinotecan, and oxaliplatin) or PAXG (cisplatin, abraxane, capecitabine, and gemcitabine) in patients with stage I-III pancreatic adenocarcinoma, resectable or borderline resectable. Currently, the active centers are 9 and the enrolled subjects are 82, that is, 31% of the expected number of patients.
We have therefore already reached an interesting number and this represents a further incentive to proceed with determination.
The centers already activated are recruiting actively and continuously and at the moment no particular critical issues have been reported. We are waiting for the opening of other centers that will actively contribute to accelerating enrollment. In addition, a new amendment will soon be submitted in which two new centers will be included (the Hospital of Rimini and San Camillo in Rome). AISP thanks all of you for the valuable support that makes our commitment to this study possible! If you would like more information, you can contact the AISP secretariat at the following address: aispsegreteria@idea-z.it. Best regards, Prof. Massimo Falconi President AISP